Advisory Committee on Immunization Practices, 66029-66030 [2016-23053]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 186 / Monday, September 26, 2016 / Notices
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2016–23073 Filed 9–23–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES (HHS)
Centers for Disease Control and
Prevention (CDC)
Breast and Cervical Cancer Early
Detection and Control Advisory
Committee (BCCEDCAC): Notice of
Charter Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the charter
for the Breast and Cervical Cancer Early
Detection and Control Advisory
Committee, Department of Health and
Human Services, has been renewed for
a 2-year period through September 12,
2018.
For information, contact Ms. Jameka
Blackmon, Designated Federal Officer,
BCCEDCAC, CDC, 1600 Clifton Road
NE., M/S K57, Atlanta, Georgia, 30329,
telephone (770) 488–4740; fax (770)
488–3230.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–23057 Filed 9–23–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK3G9T082PROD with NOTICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel: Notice of Charter
Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the charter
for the Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel, Centers for Disease
VerDate Sep<11>2014
19:40 Sep 23, 2016
Jkt 238001
Control and Prevention, Department of
Health and Human Services, has been
renewed for a 2-year period through
September 18, 2018.
For information, contact M. Chris
Langub, Ph.D., Designated Federal
Officer, Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel, Centers for Disease
Control and Prevention, Department of
Health and Human Services, 1600
Clifton Road NE., Mailstop K48, Atlanta,
Georgia 30329, telephone (770) 488–
3585 or fax (770) 488–4887.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–23054 Filed 9–23–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
PAR 13–129, Occupational Safety and
Health Research, NIOSH Member
Conflict Review.
Time and Date: 1:00 p.m.–5:00 p.m.,
EDT, October 20, 2016 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘PAR 13–129, NIOSH Member Conflict
Review.’’
Contact Person for More Information:
Nina Turner, Ph.D., Scientific Review
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
66029
Officer, NIOSH, CDC, 1095 Willowdale
Road, Mailstop G905, Morgantown,
West Virginia 26506, Telephone: (304)
285–5976.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–23056 Filed 9–23–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee.
Time and Date:
8:00 a.m.–6:00 p.m., EDT, October 19,
2016
8:00 a.m.–3:30 p.m., EDT, October 20,
2016
Place: CDC, Tom Harkin Global
Communications Center, 1600 Clifton
Road NE., Building 19, Kent ‘‘Oz’’
Nelson Auditorium, Atlanta, Georgia
30329.
Status: Open to the public, limited
only by the space available. Time will
be available for public comment. The
public is welcome to submit written
comments in advance of the meeting.
Comments should be submitted in
writing by email to the contact person
listed below. The deadline for receipt is
October 11, 2016. All written comments
must contain the name, address, and
organizational affiliation of the speaker,
as well as the topic being addressed.
Written comments should not exceed
one single-spaced typed page in length
and delivered in 3 minutes or less.
Please note that the public comment
period may end before the time
indicated, following the last call for
comments. Members of the public who
wish to provide public comments
should plan to attend the public
comment session at the start time listed.
Written comments received in advance
E:\FR\FM\26SEN1.SGM
26SEN1
mstockstill on DSK3G9T082PROD with NOTICES
66030
Federal Register / Vol. 81, No. 186 / Monday, September 26, 2016 / Notices
of the meeting will be included in the
official record of the meeting.
The meeting will be webcast live via
the World Wide Web; for instructions
and more information on ACIP please
visit the ACIP Web site: https://
www.cdc.gov/vaccines/acip/.
Purpose: The committee is charged
with advising the Director, CDC, on the
appropriate use of immunizing agents.
In addition, under 42 U.S.C. §1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for
administration to vaccine-eligible
children through the Vaccines for
Children (VFC) program, along with
schedules regarding the appropriate
periodicity, dosage, and
contraindications applicable to the
vaccines. Further, under provisions of
the Affordable Care Act, at section 2713
of the Public Health Service Act,
immunization recommendations of the
ACIP that have been adopted by the
Director of the Centers for Disease
Control and Prevention and appear on
the CDC immunization schedules must
be covered by applicable health plans.
Matters for Discussion: The agenda
will include discussions on:
Meningococcal vaccines; human
papillomavirus vaccines; influenza;
hepatitis vaccines; pertussis vaccines;
Respiratory Syncytial Virus (RSV); child
and adolescent immunization schedule;
adult immunization schedule; herpes
zoster vaccine; yellow fever vaccine;
pneumococcal vaccine and vaccine
supply. A recommendation vote is
scheduled for Hepatitis B vaccine,
pertussis vaccine, human
papillomavirus vaccines, meningococcal
vaccines, child and adolescent
immunization schedule, and adult
immunization schedule. A Vaccines for
Children (VFC) vote is scheduled for
human papillomavirus vaccines,
Hepatitis B vaccine and meningococcal
vaccines. Agenda items are subject to
change as priorities dictate.
Contact Person for More Information:
Stephanie Thomas, National Center for
Immunization and Respiratory Diseases,
CDC, 1600 Clifton Road NE., MS–A27,
Atlanta, Georgia 30329, Telephone:
(404) 639–8836; Email: ACIP@
CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
VerDate Sep<11>2014
19:40 Sep 23, 2016
Jkt 238001
Prevention and the Agency for Toxic
Substances and Disease Registry.
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–23053 Filed 9–23–16; 8:45 am]
[FR Doc. 2016–23055 Filed 9–23–16; 8:45 am]
BILLING CODE 4160–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA) GH16–007, Operations Research
(Implementation Science) for
Strengthening Global Health Protection
Implementation.
Times and dates: 9:00 a.m.–2:00 p.m.,
EDT, Panel A, October 18, 2016
(Closed); 9:00 a.m.–2:00 p.m., EDT,
Panel B, October 19, 2016 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
GH16–007 Operations Research
(Implementation Science) for
Strengthening Global Health Protection
Implementation.
Contact person for more information:
Hylan Shoob, Scientific Review Officer,
Center for Global Health (CGH) Science
Office, CGH, CDC, 1600 Clifton Road
NE., Mailstop D–69, Atlanta, Georgia
30329, Telephone: (404) 639–4796.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–16–0457]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
E:\FR\FM\26SEN1.SGM
26SEN1
]]>Agencies
[Federal Register Volume 81, Number 186 (Monday, September 26, 2016)]
[Notices]
[Pages 66029-66030]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23053]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Immunization Practices
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting of the aforementioned
committee.
Time and Date:
8:00 a.m.-6:00 p.m., EDT, October 19, 2016
8:00 a.m.-3:30 p.m., EDT, October 20, 2016
Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton
Road NE., Building 19, Kent ``Oz'' Nelson Auditorium, Atlanta, Georgia
30329.
Status: Open to the public, limited only by the space available.
Time will be available for public comment. The public is welcome to
submit written comments in advance of the meeting. Comments should be
submitted in writing by email to the contact person listed below. The
deadline for receipt is October 11, 2016. All written comments must
contain the name, address, and organizational affiliation of the
speaker, as well as the topic being addressed. Written comments should
not exceed one single-spaced typed page in length and delivered in 3
minutes or less. Please note that the public comment period may end
before the time indicated, following the last call for comments.
Members of the public who wish to provide public comments should plan
to attend the public comment session at the start time listed. Written
comments received in advance
[[Page 66030]]
of the meeting will be included in the official record of the meeting.
The meeting will be webcast live via the World Wide Web; for
instructions and more information on ACIP please visit the ACIP Web
site: https://www.cdc.gov/vaccines/acip/.
Purpose: The committee is charged with advising the Director, CDC,
on the appropriate use of immunizing agents. In addition, under 42
U.S.C. Sec. 1396s, the committee is mandated to establish and
periodically review and, as appropriate, revise the list of vaccines
for administration to vaccine-eligible children through the Vaccines
for Children (VFC) program, along with schedules regarding the
appropriate periodicity, dosage, and contraindications applicable to
the vaccines. Further, under provisions of the Affordable Care Act, at
section 2713 of the Public Health Service Act, immunization
recommendations of the ACIP that have been adopted by the Director of
the Centers for Disease Control and Prevention and appear on the CDC
immunization schedules must be covered by applicable health plans.
Matters for Discussion: The agenda will include discussions on:
Meningococcal vaccines; human papillomavirus vaccines; influenza;
hepatitis vaccines; pertussis vaccines; Respiratory Syncytial Virus
(RSV); child and adolescent immunization schedule; adult immunization
schedule; herpes zoster vaccine; yellow fever vaccine; pneumococcal
vaccine and vaccine supply. A recommendation vote is scheduled for
Hepatitis B vaccine, pertussis vaccine, human papillomavirus vaccines,
meningococcal vaccines, child and adolescent immunization schedule, and
adult immunization schedule. A Vaccines for Children (VFC) vote is
scheduled for human papillomavirus vaccines, Hepatitis B vaccine and
meningococcal vaccines. Agenda items are subject to change as
priorities dictate.
Contact Person for More Information: Stephanie Thomas, National
Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton
Road NE., MS-A27, Atlanta, Georgia 30329, Telephone: (404) 639-8836;
Email: ACIP@CDC.GOV.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both the Centers for Disease Control and Prevention and the Agency for
Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2016-23053 Filed 9-23-16; 8:45 am]
BILLING CODE 4160-18-P
